장마감
로그인 회원가입
NRXP
NRXP
NRX Pharmaceuticals Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$3.63
-0.12 ▼ -3.20%
🌙 7월 27일 7:45 PM ET (한국 7/28 08:45)
$3.64
+0.01 ▲ +0.28%

엔알엑스 파마슈티컬스(NRXP) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$152M
스몰캡
P/E
-
배당수익률
없음
52주 위치
59%
저점 +124% · 고점 -28%
애널리스트
적극 매수
C
Fundamental health
vs. 미분류 초소형주· based on 3 axes
수익성
산출 불가 (적자)
성장
Top 26%
밸류에이션
Top 50%
재무 안정
Top 92%
Index -P/E -EPS (ttm) -1.28Insider Own 11.62%Shs Outstand 41.9MPerf Week -13.16%
Market Cap 0.15BForward P/E 10.3EPS next Y 194.21%Insider Trans -Shs Float 37.1MPerf Month 1.97%
Enterprise Value 0.15BPEG -EPS next Q -0.11Inst Own 15.05%Short Float 16.72%Perf Quarter 23.47%
Income -0.02BP/S 66.49EPS this Y 72.07%Inst Trans -1.31%Short Ratio 5.23Perf Half Y 67.28%
Sales 0.00BP/B -EPS next 5Y -ROA -251.79%Short Interest 6.20MPerf YTD 33.95%
Book/sh -0.41P/C 22.69EPS past 3/5Y 39.52% 38.42%ROE -52W High -28.19% ($5.05)Perf Year 21%
Cash/sh 0.16P/FCF -Sales past 3/5Y -ROIC -52W Low 124.07% ($1.62)Perf 3Y 3.3%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM 36.33%Gross Margin 37.11%Volatility(W/M) 9.24% 7.99%Perf 5Y -97.97%
Dividend TTM -EV/Sales 63.96Sales Y/Y TTM -Oper. Margin -749.67%ATR (14) 0.33Perf 10Y -
Dividend Ex-Date -Quick Ratio 0.29EPS Q/Q 86.84%Profit Margin -1070.26%RSI (14) 40.58Recom 1
Dividend Gr. 3/5Y -Current Ratio 0.29Sales Q/Q -SMA20 -11.68% ($4.11)Beta 2.16Target Price $42
Payout -Debt/Eq -Earnings 2026/5/15SMA50 -7.98% ($3.94)Rel Volume 0.78Prev Close $3.75
Employees 29LT Debt/Eq -EPS/Sales Surpr. -119.14% -94.5%SMA200 30.38% ($2.78)Avg Volume(3M) 1.19MPrice $3.63
IPO 2017/12/4Option/Short Yes/YesTrades 3590Volume 925,365Change -3.2%
Quarterly earnings trend SEC filings · USD
23.9
24.3
24.6
24.9
25.3
25.6
25.9
26.3
Revenue Net income 최근 분기: 매출 $1M · 순이익 $-1M (YoY +74%)

📊 NRX Pharmaceuticals Inc (NRXP) Investment Analysis

What kind of company is NRX Pharmaceuticals Inc?

엔알엑스 파마슈티컬스(NRXP)
Healthcare · Biotechnology
Small-Cap — Low Volume, High Volatility

💊 A clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders and life-threatening severe diseases. It focuses on areas with significant unmet medical needs, such as major depressive disorder with suicidal ideation, and its core business is the clinical development of candidate compounds and the regulatory approval process.

Learn more about NRX Pharmaceuticals Inc →
Market Cap
$0.2B
Approx. KRW 0.2 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank4304
Employees29people
IPO2017/12/04
Current Price$3.63 ≈ 4,973원
NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 18일 (월) · 장 시작 전 EPS -150.0% 매출 -86.7%
🔔 Earnings release 2026년 5월 15일 (금) · 장 시작 전 EPS -119.1% 매출 -94.5%
🔔 Earnings release 2026년 3월 23일 (월) · 장 마감 후 EPS -150.0% 매출 -86.7%

Is it profitable?

Both profitability & finances need caution
Review management risk carefully before investing
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
-749.7%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Net Margin
Share of revenue left after taxes and interest are paid
-1070.3%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
37.1%
✓ 평균
My positionMid-range
Low range Average High range
Biotechnology 초소형주 Median 53.4% · Bottom 43%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROA
Annual earnings relative to total company assets
-251.8%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Current Ratio
Liquid assets available to cover liabilities due within a year
0.29
✓ 위험
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
0.29
✓ 위험
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$42.00
현재가 대비 +1057.0%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
10.30배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
내년 EPS 예상 성장률
+194.2%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance
Slight tendency to beat estimates
2
예상 상회
0
예상 부합
1
예상 하회
67%
상회 비율
+79.6%
평균 서프라이즈
2026.05.18
하회
-150.0%
2026.05.15
상회
실적 $-0.04 · 예상 $-0.11 +59.6%
2026.03.23
상회
실적 $0.18 · 예상 $-0.08 +329.1%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Strong Growth
Above the industry average, both historically and going forward
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+72.1%
양호
My positionMid-range
Low range Average High range
미분류 초소형주 Median 29.4% · Top 27%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+194.2%
우수
My positionTop 25%
Low range Average High range
미분류 초소형주 Median 40.2% · Top 14%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+39.5%
양호
My positionMid-range
Low range Average High range
미분류 초소형주 Median 25.4% · Top 37%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+38.4%
우수
My positionTop 25%
Low range Average High range
미분류 초소형주 Median 14.6% · Top 25%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -166%p below the market
NRXP -98.0% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-166.3%p
Significantly behind the market
vs Health Care (XLV)
-122.5%p
Significantly behind the sector average
1-year basis
vs S&P 500
+5.0%p
roughly in line with the market
vs Health Care (XLV)
+1.3%p
roughly in line with the sector average
Rank among peers
5-year return Lower-Mid (lower 38%) Based on 245 peers
1-year return Top 19% Based on 315 peers
Current position within 52-week range
Low (-124.1%p) High (-28.2%p)
Current price is 124.1% above the 52-week low and 28.2% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-22.9%
Annualized volatility
94.4%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔵
Current diagnosis · 2026-07-27
Oversold zone — rebound potential

Current price $3.63 fell below the lower band ($3.65). Selling pressure excessive; worth watching for a short-term bounce. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-07-27
Neutral zone — weak trend

MACD 0.037 · Signal 0.106 · Hist -0.069. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 40.6 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 5.6.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average
Cheap on Vs. Earnings, Pricey on Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵 Vs. Earnings Cheap
🧾 Vs. Sales Pricey
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
10.30x
✓ Very cheap
My positionTop 25%
Low range Average High range
Biotechnology median 20.98x · Top 24% — relatively cheap within the industry
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
66.49x
✓ Pricey
My positionBottom 25%
Low range Average High range
Biotechnology 초소형주 median 11.24x · Bottom 24% — expensive within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
Analyst target price (reference)
$42.00 vs. current price +1057.0%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology

Who owns it?

Ownership backdrop is unfavorable
Institutional net selling -1.3% · Short interest elevated 16.7% · Short interest up +8.0pp over last 90d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
-1.3%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 15.1%
Retail-led
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 11.6%
Founder/management large holders (strong skin-in-the-game)
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 73.3%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
16.7%
Somewhat high
Healthcare 초소형주 Median 3.9%
Past 90 days 📈 +8.0%p increase
Short interest days to cover
5.2 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 41.9M주
Float (tradable shares) 37.1M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding NRXP

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
NRXP NRXP This Stock
$152.3M- - - - -3.2%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 엔알엑스 파마슈티컬스(NRXP)?

엔알엑스 파마슈티컬스(NRXP) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of NRXP?

The market cap of NRXP is approximately $152M, ranking 4,304 within its sector.

What is the 52-week high and low for NRXP?

NRXP has recorded a 52-week high of $5.05 and a low of $1.62.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.